Open AccessZidovudine impairs immunological recovery on first-line antiretroviral therapy
Author(s) -
Gilles Wandeler,
Thomas Gsponer,
Lloyd Mulenga,
Daniela Garone,
Robin Wood,
Mhairi Maskew,
Hans Prozesky,
Christopher J. Hoffmann,
Jochen Ehmer,
Diana Dickinson,
Mary Ann Davies,
Matthias Egger,
Olivia Keiser
Publication year - 2013
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e328362d887
Subject(s) - zidovudine , medicine , regimen , confidence interval , odds ratio , logistic regression , cohort , immunology , antiretroviral therapy , multicenter aids cohort study , anemia , viral load , human immunodeficiency virus (hiv) , viral disease
Zidovudine (ZDV) is recommended for first-line antiretroviral therapy (ART) in resource-limited settings. ZDV may, however, lead to anemia and impaired immunological response. We compared CD4+ cell counts over 5 years between patients starting ART with and without ZDV in southern Africa.